PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells
- 27 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 18 (9), 1392-1401
- https://doi.org/10.1158/1541-7786.MCR-19-0592
Abstract
EGFR inhibitors have shown poor efficacy in head and neck squamous cell carcinoma (HNSCC) with demonstrated involvement of the insulin-like growth factor-1 receptor (IGF1R) in resistance to EGFR inhibition. IGF1R activates the PI3K-Akt pathway, which phosphorylates proline-rich Akt substrate of 40 kDa (PRAS40) to cease mTOR inhibition resulting in increased mTOR signaling. Proliferation assays separated six HNSCC cell lines into two groups: sensitive to EGFR inhibition or resistant; all sensitive cell lines demonstrated reduced sensitivity to EGFR inhibition upon IGF1R activation. Reverse phase protein microarray analysis and immunoblot identified a correlation between increased PRAS40 phosphorylation and IGFR-mediated resistance to EGFR inhibition. In sensitive cell lines, PRAS40 phosphorylation decreased 44%-80% with EGFR inhibition and was restored to 98%-196% of control by IGF1R activation, while phosphorylation was unaffected in resistant cell lines. Possible involvement of mTOR in this resistance mechanism was demonstrated through a similar pattern of p70S6K phosphorylation. However, addition of temsirolimus, an mTORC1 inhibitor, was insufficient to overcome IGF1R-mediated resistance and suggested an alternative mechanism. Forkhead box O3a (FOXO3a), which has been reported to complex with PRAS40 in the cytoplasm, demonstrated a 6-fold increase in nuclear to cytoplasmic ratio upon EGFR inhibition that was eliminated with concurrent IGF1R activation. Transcription of FOXO3a-regulated TRAIL and PTEN-induced putative kinase-1 (PINK1) was increased with EGFR inhibition in sensitive cell lines; this effect was diminished with IGF1R stimulation.Keywords
Other Versions
Funding Information
- NIH
- NIDCR (DE019477)
- UVA Cancer Center
- UVA Department of Otolaryngology- Head and Neck Surgery Pilot Project
- Ruth L. Kirschstein T32 Institutional Research Award (CA009109-42)
This publication has 27 references indexed in Scilit:
- Functional Protein Pathway Activation Mapping of the Progression of Normal Skin to Squamous Cell CarcinomaCancer Prevention Research, 2012
- Activation of the Insulin-like Growth Factor-1 Receptor Induces Resistance to Epidermal Growth Factor Receptor Antagonism in Head and Neck Squamous Carcinoma CellsMolecular Cancer Therapeutics, 2011
- Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interactionJournal of Cellular Biochemistry, 2010
- PRAS40 Is an Insulin-Regulated Inhibitor of the mTORC1 Protein KinaseMolecular Cell, 2007
- Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40Nature, 2007
- Upstream and downstream of mTORGenes & Development, 2004
- Serum Levels of Insulin Growth Factor (IGF-I) and IGF-Binding Protein Predict Risk of Second Primary Tumors in Patients with Head and Neck CancerClinical Cancer Research, 2004
- Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatmentAnti-Cancer Drugs, 2003
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003
- Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion frontOncogene, 2001